The OMERACT MRI in arthritis working group - Update on status and future research priorities

Mikkel Østergaard*, Paul Bird, Frédérique Gandjbakhch, Iris Eshed, Ida K. Haugen, Espen A. Haavardsholm, Siri Lillegraven, Violaine Foltz, Daniel Glinatsi, Charles Peterfy, Bo Ejbjerg, Pernille Bøyesen, Philip J. Mease, Kay Geert Hermann, Paul Emery, Harry K. Genant, Philip G. Conaghan

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftArtikelForskningpeer review

Abstract

Objective. To provide an update on the status and future research priorities of the Outcome Measures in Rheumatology (OMERACT) magnetic resonance imaging (MRI) in arthritis working group. Methods. A summary is provided of the activities of the group within rheumatoid arthritis (RA), psoriatic arthritis (PsA), and osteoarthritis (OA), and its research priorities. Results. The OMERACT RA MRI score (RAMRIS) evaluating bone erosion, bone edema (osteitis), and synovitis is now the standard method of quantifying articular pathology in RA trials. Cartilage loss is another important part of joint damage, and at the OMERACT 12 conference, we provided longitudinal data demonstrating reliability and sensitivity to change of the RAMRIS JSN component score, supporting its use in future clinical trials. The MRI group has previously developed a PsA MRI score (PsAMRIS). At OMERACT 12, PsAMRIS was evaluated in a randomized placebo-controlled trial of patients with PsA, demonstrating the responsiveness and discriminatory ability of applying the PsAMRIS to hands and feet. A hand OA MRI score (HOAMRIS) was introduced at OMERACT 11, and has subsequently been further validated. At OMERACT 12, good cross-sectional interreader reliability, but variable reliability of change scores, were reported. Potential future research areas were identified at the MRI session at OMERACT 12 including assessment of tenosynovitis in RA and enthesitis in PsA and focusing on alternative MRI techniques. Conclusion. MRI has been further developed and validated as an outcome measure in RA, PsA, and OA. The group will continue its efforts to optimize the value of MRI as a robust biomarker in rheumatology clinical trials.

OriginalsprogEngelsk
Sider (fra-til)2470-2472
Antal sider3
TidsskriftJournal of Rheumatology
Vol/bind42
Udgave nummer12
DOI
StatusUdgivet - dec. 2015

Fingeraftryk

Udforsk hvilke forskningsemner 'The OMERACT MRI in arthritis working group - Update on status and future research priorities' indeholder.

Citationsformater